ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06253130

Public ClinicalTrials.gov record NCT06253130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 6:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors

Study identification

NCT ID
NCT06253130
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Eikon Therapeutics
Industry
Enrollment
156 participants

Conditions and interventions

Interventions

  • IMP1734 Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 89 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 10, 2023
Primary completion
May 31, 2027
Completion
Nov 30, 2027
Last update posted
Mar 22, 2026

2023 – 2027

United States locations

U.S. sites
23
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
The University of Arizona Cancer Center Tucson Arizona 85719 Recruiting
University of Arkansas Winthrop P. Rockefeller Cancer Institute Little Rock Arkansas 72205 Recruiting
Hoag Health Center Irvine Irvine California 92618 Recruiting
University California Irvine Irvine California 92868 Withdrawn
Sharp Memorial Hospital San Diego California 92123 Withdrawn
University of California San Francisco (UCSF) San Francisco California 94158 Withdrawn
Sarah Cannon Research Institute Health One Denver Colorado 80218 Recruiting
Smilow Cancer Hospital at Yale New Haven New Haven Connecticut 06511 Recruiting
Advent Health Research Institute Celebration Florida 34747 Recruiting
Sylvester Comprehensive Cancer Center Miami Florida 33136 Recruiting
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109 Recruiting
Karmanos Cancer Institute Detroit Michigan 48201 Recruiting
Henry Ford Health Detroit Michigan 48202 Recruiting
University of Minnesota-Clinical Research Unit Minneapolis Minnesota 55455 Recruiting
Washington University - Siteman Cancer Center St Louis Missouri 63110 Withdrawn
John Theurer Cancer Center Hackensack New Jersey 07601 Withdrawn
Cayuga Medical Center Ithaca New York 14850 Withdrawn
Lifespan Cancer Institute Providence Rhode Island 02903 Recruiting
Medical University of South Carolina (MUSC) - Hollings CC Charleston South Carolina 29425 Recruiting
West Cancer Center & Research Institute Germantown Tennessee 38138 Recruiting
Sarah Cannon Research Institue Oncology Nashville Tennessee 37203 Recruiting
START - South Texas Accelerated Research Therapeutics San Antonio Texas 78229 Withdrawn
START Mountain Region West Valley City Utah 84119 Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06253130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 22, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06253130 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →